Novel radiolabeled ligand, Para-chloro-2-[<sup>18</sup>F]fluoroethyletomidate (CETO) compared to [<sup>11</sup>C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)

Emily Goodchild(St Bartholomew's Hospital), Morris J. Brown(Queen Mary University of London), Samuel O’Toole(Royal Hallamshire Hospital), Victoria Warnes(Cambridge University Hospitals NHS Foundation Trust), James MacFarlane(University of Cambridge), Kate Laycock(St Bartholomew's Hospital), Jackie Salsbury(Queen Mary University of London), Russell Senanayake(University of Cambridge), Dan Gillett, Giulia Argentesi(St Bartholomew's Hospital), Waiel Bashari(University of Cambridge), Franklin I. Aigbirhio(University of Cambridge), Mark Gurnell(University of Cambridge), Xi‐Lin Wu(Queen Mary University of London), Stefan Hader(University of Cambridge), William Drake, Kennedy Cruickshank, Nicholas J. Bird(Cambridge University Hospitals NHS Foundation Trust), Anju Sadhev, Heok Cheow(Cambridge University Hospitals NHS Foundation Trust), István Boros(University of Cambridge)
Endocrine Abstracts
October 27, 2022
Cited by 1


Related Papers